AI Article Synopsis
- Imatinib (IM) is the main treatment for chronic-phase CML, but some patients develop resistance, making it less effective.
- The study investigates miR-629-5p levels in extracellular vesicles from both IM-sensitive and IM-resistant CML cell lines and its effect on cell behavior.
- Results show that EVs from resistant cells increase miR-629-5p levels in sensitive cells, activate the SENP2/PI3K/AKT/mTOR pathway, and contribute to IM resistance in CML.
Article Abstract
Background: Imatinib (IM) is the primary treatment for patients with chronic-phase CML (CML-CP). However, an increasing number of CML-CP patients have developed resistance to IM. Our study aims to explore the expression of miR-629-5p in extracellular vesicles (EVs) from both IM-sensitive (K562) and resistant (K562-Re) CML cell lines and to investigate the impact of regulating miR-629-5p expression on the biological characteristics of K562 and K562-Re cells.
Methods: Assess miR-629-5p expression levels in IM-sensitive and resistant CML cell lines. Separate EVs and verify it. EVs from K562-Re cells were co-cultured with K562 cells to detect the expression level of miR-629-5p. Target genes of miR-629-5p were determined and validated through luciferase experiments. Examined by manipulating miR-629-5p expression in cells using transfection techniques. The expression level of phosphorylated proteins in the PI3K/AKT/mTOR signaling pathway after IM was detected in CML cell lines. In K562-Re cells, the expression level of phosphorylated protein in the PI3K/AKT/mTOR signaling pathway was detected after single transfection of miR-629-5p inhibitor and cotransfection of miR-629-5p inhibitor and siSENP2.
Results: Increasing concentrations of EVs from K562-Re cells elevated miR-629-5p expression levels. The expression levels of miR-629-5p in CML cells varied with IM concentration and influenced the biological characteristics of cells. SENP2 was identified as a target gene of miR-629-5p. Furthermore, miR-629-5p was found to modulate the SENP2/PI3K/AKT/mTOR pathway, impacting IM resistance in CML cells.
Conclusion: EVs from IM-resistant CML cells alter the expression of miR-629-5p in sensitive cells, activating the SENP2/PI3K/AKT/mTOR pathway and leading to IM resistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/16078454.2024.2379597 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of Serum Cell-Free miRNA Panel for Identification of Central Precocious Puberty and Premature Thelarche in Girls.
Biochemistry (Mosc)
October 2024
Central laboratory, Suzhou Bay Clinical College, Xuzhou Medical University, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, 215200, China.
Precocious puberty of children, especially girls, has attracted more and more public attention in recent years. In clinic practice, there is a lack of both convenient and effective way to identify central precocious puberty (CPP) and premature thelarche (PT). In this study, we enrolled total 88 girls [28 cases of CPP, 37 cases of PT, as well as 23 cases of normal control (NC)] as a training cohort, and another 270 subjects (92 cases of CPP, 122 cases of PT and 56 cases of NC) as a validation cohort.
View Article and Find Full Text PDFMiR-629-5p May serve as a biomarker for pediatric acute respiratory distress syndrome and can regulate the inflammatory response.
Pediatr Neonatol
August 2024
Pediatric Intensive Care Unit, Xingtai People's Hospital, Xingtai, 054000, China. Electronic address:
Objective: Circulating microRNAs (miRNAs) are associated with pediatric acute respiratory distress syndromes (PARDS). This study analyzed the clinical significance and potential mechanism of microRNA (miR)-629-5p in PARDS.
Methods: 82 children with PARDS and 82 controls were enrolled.
Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p/SENP2/PI3K/AKT/mTOR axis.
Hematology
December 2024
Department of Hematology, Guizhou Provincial People's Hospital, Guiyang, People's Republic of China.
Article Synopsis
- Imatinib (IM) is the main treatment for chronic-phase CML, but some patients develop resistance, making it less effective.
- The study investigates miR-629-5p levels in extracellular vesicles from both IM-sensitive and IM-resistant CML cell lines and its effect on cell behavior.
- Results show that EVs from resistant cells increase miR-629-5p levels in sensitive cells, activate the SENP2/PI3K/AKT/mTOR pathway, and contribute to IM resistance in CML.
MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment.
J Headache Pain
May 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy.
Article Synopsis
- Migraine treatment with monoclonal antibodies, specifically erenumab, shows potential in identifying circulating microRNAs (miRNAs) as biomarkers for different migraine types (episodic and chronic).
- The study assessed miRNA levels in women aged 25-50 with episodic or chronic migraines before and after a 16-week treatment regimen, finding significant improvements in migraine symptoms.
- Results indicated varied expression levels of specific miRNAs related to treatment response, suggesting their potential role as epigenetic biomarkers for migraine management.
Altered Plasma microRNA Signature in Hospitalized COVID-19 Patients Requiring Oxygen Support.
Microorganisms
February 2024
IrsiCaixa, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
To discover potential micro(mi)RNA biomarkers of SARS-CoV-2 infection and disease progression, large-scale deep-sequencing analysis of small RNA expression was performed on plasma samples from 40 patients hospitalized for SARS-CoV-2 infection (median 13.50 [IQR 9-24] days since symptoms initiation) and 21 healthy noninfected individuals. A total of 1218 different miRNAs were identified.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!